tecastemizole has been researched along with risperidone in 5 studies
| Studies (tecastemizole) | Trials (tecastemizole) | Recent Studies (post-2010) (tecastemizole) | Studies (risperidone) | Trials (risperidone) | Recent Studies (post-2010) (risperidone) |
|---|---|---|---|---|---|
| 18 | 0 | 3 | 6,924 | 1,505 | 2,477 |
| Protein | Taxonomy | tecastemizole (IC50) | risperidone (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.015 | |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.0027 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.0097 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 5.2734 | |
| Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | 4.1901 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.0167 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.0991 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.026 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.0096 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.799 | |
| D(1A) dopamine receptor | Homo sapiens (human) | 0.479 | |
| Histamine H2 receptor | Homo sapiens (human) | 1.483 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.01 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.0016 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.0057 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.799 | |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.0027 | |
| 5-hydroxytryptamine receptor 2C | Mus musculus (house mouse) | 0.0015 | |
| Alpha-1A adrenergic receptor | Homo sapiens (human) | 0.0105 | |
| 5-hydroxytryptamine receptor 2A | Mus musculus (house mouse) | 0.0015 | |
| Histamine H1 receptor | Homo sapiens (human) | 0.4515 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.024 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.023 | |
| D(2) dopamine receptor | Mus musculus (house mouse) | 0.023 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.0154 | |
| 5-hydroxytryptamine receptor 2B | Mus musculus (house mouse) | 0.0015 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.6303 | |
| 5-hydroxytryptamine receptor 1A | Mus musculus (house mouse) | 0.43 | |
| Nuclear receptor subfamily 3 group C member 3 | Bos taurus (cattle) | 4.1901 | |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 1.6 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cavalli, A; De Ponti, F; Poluzzi, E; Recanatini, M | 1 |
| Keserü, GM | 1 |
| Li, J; Rajamani, R; Reynolds, CH; Tounge, BA | 1 |
| Jia, L; Sun, H | 1 |
| Caron, G; Ermondi, G; Visentin, S | 1 |
5 other study(ies) available for tecastemizole and risperidone
| Article | Year |
|---|---|
Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
Topics: Anti-Arrhythmia Agents; Cation Transport Proteins; Cluster Analysis; Databases, Factual; Ether-A-Go-Go Potassium Channels; Long QT Syndrome; Models, Molecular; Molecular Conformation; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2002 |
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
A two-state homology model of the hERG K+ channel: application to ligand binding.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Ligands; Models, Biological; Models, Molecular; Potassium Channels, Voltage-Gated; Protein Binding; Protein Conformation | 2005 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
Topics: Ether-A-Go-Go Potassium Channels; Humans; Hydrophobic and Hydrophilic Interactions; Models, Molecular; Potassium Channel Blockers; Quantitative Structure-Activity Relationship | 2009 |